Latest news with #Vafseo
Yahoo
25-07-2025
- Business
- Yahoo
H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 Best Performing Penny Stocks So Far in 2025. On June 4, H.C. Wainwright analysts initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) and gave it a 'Buy' rating with a price target of $8. This decision was based on confidence in the company's drug, Vafseo (vadadustat), which is used to treat anemia in adults with chronic kidney disease (CKD) who are on dialysis. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. In March 2024, Akebia Therapeutics, Inc. (NASDAQ:AKBA) received FDA approval for Vafseo (vadadustat) for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Vafseo became available in the US market starting January 2025. Currently, Vafseo is being rolled out for dialysis patients. However, there is also potential for expansion in the non-dialysis segment. Akebia Therapeutics, Inc. (NASDAQ:AKBA) plans to start a Phase 3 trial for the use of Vafseo (vadadustat) in treating anemia in late-stage CKD patients who are not on dialysis. H.C. Wainwright analysts expect further growth for Akebia Therapeutics, Inc. (NASDAQ:AKBA) as the drug gains acceptance among dialysis organizations, including large ones. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a fully integrated biopharmaceutical company focused on developing and commercializing therapies for kidney disease. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22-07-2025
- Business
- Yahoo
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C. Wainwright Kidney Conference, emphasizing the rollout of its oral anemia treatment Vafseo, prescribed by over 640 physicians in Q1. A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections. With initial pricing at $15,500 annually and post-TDAPA rates expected near $2,500, Akebia targets a $4–5 billion opportunity by expanding to non-dialysis CKD patients. A pilot launch with a major dialysis provider is set for Q3, covering 75–200 clinics, with broader availability expected in Q4 and a Phase 3 trial planned for later this year. Akebia also reaffirmed strong sales momentum for Auryxia, its existing kidney treatment, despite generic competition. The company's R&D pipeline includes AKB-909O for acute kidney injury and AKB-10108 for retinopathy of prematurity. Akebia aims to position Vafseo as the standard of care across CKD stages, supported by its ongoing VOICE trial targeting reduced hospitalizations. This strategic push underscores Akebia's focus on delivering innovative solutions for chronic kidney care and expanding market reach amid competitive challenges. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. It has two FDA-approved products, Auryxia (ferric citrate) and Vafseo, both of which target complications of kidney disease, such as anemia and hyperphosphatemia. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential. On May 29, Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Akebia Therapeutics, Inc. (NASDAQ:AKBA) and set a price target of $7.00. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) holds potential for growth, as discussions with key opinion leaders (KOLs) point towards considerable momentum for its product Vafseo in the dialysis market. Vafseo currently holds approval for the treatment of anemia in chronic kidney disease (CKD) dialysis patients, and is a notable revenue growth driver for the company, according to Ruiz. He further said that the non-dialysis CKD market shows another notable opportunity for the company, dependent on the success of the Phase 3 VALOR trial, anticipated to start in H2 2025. The analyst reasoned that the trial holds the potential to enhance the company's market potential and cause significant expansion of Vafseo's label. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes therapeutics for kidney diseases and renal and metabolic disorders. Its product pipeline includes Auryxia and Vadadustat. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
30-06-2025
- Business
- Yahoo
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.
Yahoo
29-06-2025
- Business
- Yahoo
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
